To read the full article sign up for free or sign in.

Celltrion doubles pace for COVID-19 antibody treatment CT-P59

Aug. 4, 2020

HONG KONG – Incheon, South Korea-based Celltrion Inc. is rapidly advancing CT-P59, its antiviral antibody treatment for the COVID-19 virus, after receiving its second green light to begin phase I trials.

BioWorld BioWorld Asia Clinical Regulatory Coronavirus Asia-Pacific

Today's news in brief

BioWorld

BioWorld briefs for Nov. 21, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 21, 2024.

J&J’s Ottava robotic system approved for US pivotal trial

BioWorld MedTech

Johnson & Johnson received U.S. FDA investigational device exemption to begin the pivotal clinical trial for the Ottava robotic surgical system. If the trial goes...

Illustration of Microglia cells (red) in Alzheimer´s disease

Less microglia activity may improve APOE4’s effect in Alzheimer’s

BioWorld

Reducing microglial activity in the presence of apolipoprotein E4 (APOE4) has uncovered a mechanism associated with the deposition of misfolded amyloid and tau in...

‘Evo’ AI can design complete genomes

BioWorld Science

The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...

Upgrade your daily dose of biopharma and medtech news

Celltrion doubles pace for COVID-19 antibody treatment CT-P59